A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 3,510 shares of BMRN stock, worth $233,871. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,510
Previous 3,070 14.33%
Holding current value
$233,871
Previous $253,000 2.37%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$69.02 - $93.84 $30,368 - $41,289
440 Added 14.33%
3,510 $247,000
Q2 2024

Jul 26, 2024

BUY
$74.43 - $92.22 $39,001 - $48,323
524 Added 20.58%
3,070 $253,000
Q1 2024

Apr 24, 2024

SELL
$83.81 - $99.0 $25,562 - $30,195
-305 Reduced 10.7%
2,546 $222,000
Q4 2023

Feb 09, 2024

BUY
$76.22 - $98.51 $3,201 - $4,137
42 Added 1.5%
2,851 $275,000
Q3 2023

Oct 24, 2023

SELL
$85.07 - $94.48 $106,592 - $118,383
-1,253 Reduced 30.85%
2,809 $249,000
Q2 2023

Jul 13, 2023

SELL
$86.68 - $100.3 $89,020 - $103,008
-1,027 Reduced 20.18%
4,062 $352,000
Q1 2023

May 11, 2023

SELL
$87.74 - $117.27 $92,039 - $123,016
-1,049 Reduced 17.09%
5,089 $495,000
Q4 2022

Feb 08, 2023

BUY
$80.93 - $108.63 $37,227 - $49,969
460 Added 8.1%
6,138 $635,000
Q3 2022

Oct 17, 2022

SELL
$82.16 - $96.94 $189,132 - $223,155
-2,302 Reduced 28.85%
5,678 $481,000
Q2 2022

Jul 13, 2022

SELL
$71.48 - $86.85 $32,451 - $39,429
-454 Reduced 5.38%
7,980 $661,000
Q1 2022

May 12, 2022

SELL
$74.28 - $92.69 $237,027 - $295,773
-3,191 Reduced 27.45%
8,434 $650,000
Q4 2021

Feb 03, 2022

SELL
$71.72 - $91.47 $706,800 - $901,436
-9,855 Reduced 45.88%
11,625 $1.03 Million
Q3 2021

Nov 02, 2021

BUY
$74.77 - $85.47 $247,787 - $283,247
3,314 Added 18.24%
21,480 $1.66 Million
Q2 2021

Aug 10, 2021

BUY
$75.51 - $84.79 $646,969 - $726,480
8,568 Added 89.27%
18,166 $1.52 Million
Q1 2021

May 07, 2021

BUY
$74.73 - $90.69 $310,428 - $376,726
4,154 Added 76.3%
9,598 $724,000
Q4 2020

Feb 04, 2021

BUY
$72.61 - $90.2 $93,449 - $116,087
1,287 Added 30.96%
5,444 $477,000
Q3 2020

Oct 29, 2020

SELL
$71.87 - $131.03 $5,318 - $9,696
-74 Reduced 1.75%
4,157 $316,000
Q2 2020

Jul 27, 2020

BUY
$79.55 - $124.22 $336,576 - $525,574
4,231 New
4,231 $521,000
Q1 2018

May 09, 2018

SELL
$77.67 - $92.63 $194,874 - $232,408
-2,509 Closed
0 $0
Q4 2017

Feb 22, 2018

SELL
$80.76 - $95.13 $2,261 - $2,663
-28 Reduced 1.1%
2,509 $0
Q3 2017

Nov 07, 2017

BUY
$80.6 - $94.95 $15,475 - $18,230
192 Added 8.19%
2,537 $236,000
Q2 2017

Aug 08, 2017

BUY
N/A
2,345
2,345 $213,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.